LM PCI Optimization
Pearls from the ongoing LM PCI Trials

Opening Remarks

Jens Flensted Lassen MD, PH.D., FESC.
Clinical Director, Associate professor
Cardiac Catheterization Laboratory
Department of Cardiology, The Heart Centre,
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark

Randomized LM PCI vs. CABG trials

	NOBLE	EXCEL
N patients, sites	1,200 @ 26 EU sites	1,900 @ 126 sites in 17 countries
DES	Biomatrix BES recommended	Xience EES
LM location	Ostial, shaft, or bifurcation	Ostial, shaft, or bifurcation
LM severity	Angio DS >50% or FFR ≤0.80	Angio DS ≥70% or ≥50% - <70% + either FFR ≤0.80 or IVUS MLA ≤6.0 mm^2 or non-invasive evidence of extensive ischemia
Other anatomic inclusion criteria	≤3 additional non-complex lesions (excludes length >25 mm, CTO, 2-stent bifurcation, calcified or tortuous vessels)	Syntax Score ≤32
Primary endpoint	D, CVA, non-index MI, revasc	D, CVA, MI
Timing of primary EP	2 years	Median 3 years
Duration of follow-up	5 years	5 years

LM PCI Optimization
Pearls from the ongoing LM PCI Trials

EXCEL & NOBLE.

late braking trials TCT 2016,

Monday October 31.

Simultaneous publication in

NEJM & The Lancet

Proximal Incomplete Apposition:





Courtesy of Nicolas Foin


EBC


EBC


EBC


EBC